Welcome to our dedicated page for Senti Bioscience news (Ticker: SNTI), a resource for investors and traders seeking the latest updates and insights on Senti Bioscience stock.
Senti Biosciences, Inc. (SNTI) is a clinical-stage biotechnology company pioneering gene circuit-engineered cell therapies for cancer treatment. This page serves as the definitive source for corporate announcements, clinical trial updates, and scientific advancements related to their synthetic biology platform.
Investors and researchers will find timely updates on SNTI's CAR-NK cell therapy programs targeting hematologic malignancies and solid tumors. The resource consolidates press releases covering clinical milestones, strategic collaborations, and regulatory developments while explaining complex biotechnological concepts in accessible language.
Key content includes updates on lead programs for acute myeloid leukemia (AML) and hepatocellular carcinoma (HCC), partnership announcements with biopharma innovators, and progress reports on their logic-gated Gene Circuit technology platform. All materials maintain rigorous adherence to factual reporting of verifiable company developments.
Bookmark this page for structured access to SNTI's latest scientific presentations, manufacturing updates, and peer-reviewed research findings. Check regularly for authoritative information directly from corporate communications and verified media sources.
Senti Biosciences (NASDAQ: SNTI) has released a Virtual Investor segment featuring Dr. Kanya Rajangam, President, Head of R&D and Chief Medical Officer, discussing recently presented positive preliminary Phase 1 clinical trial data for SENTI-202 at AACR Annual Meeting 2025.
SENTI-202 is a pioneering off-the-shelf Logic Gated selective CD33 OR FLT3 NOT EMCN chimeric antigen receptor natural killer (CAR-NK) cell therapy being developed for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML).
Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotech company focused on next-generation cell and gene therapies, has announced its upcoming presentation at the Citizens JMP Life Sciences Conference in New York. The presentation is scheduled for May 8th, 2025, at 1:00 PM ET.
Dr. Timothy Lu, Co-Founder and CEO, will lead the presentation, which will highlight recent positive preliminary clinical results of their lead program, SENTI-202, in treating patients with Relapsed/Refractory AML. Management will also be available for one-on-one meetings with qualified investors attending the conference.
Interested parties can access the live video webcast through Senti Bio's website investor section and will remain available for 90 days after the event.
Senti Bio (NASDAQ: SNTI) has reported positive preliminary results from its Phase 1 clinical trial of SENTI-202, a first-in-class off-the-shelf CAR NK cell therapy for treating relapsed/refractory AML. The data was presented at the AACR Annual Meeting 2025.
Key findings include:
- 5 of 7 evaluable patients achieved overall response rate across all dose cohorts
- 4 of 4 complete remission patients were measurable residual disease negative
- Longest durability observed at 8+ months
- No dose limiting toxicities reported
- Preliminary recommended Phase 2 dose identified as 1.5 x 109 CAR NK cells
The company reported Q1 2025 preliminary financials with cash and equivalents of $33.8 million, R&D expenses of $9.3 million, and a net loss of $14.1 million ($1.41 per share). Additionally, Senti Bio announced the stoppage of enrollment in their SENTI-301A trial for HCC due to dose limiting toxicities.
Senti Biosciences (SNTI) announced it will host a conference call and webcast on Monday, April 28, 2025 at 8:30 AM ET to discuss new Phase 1 clinical data for SENTI-202 being presented at the American Association for Cancer Research (AACR) Annual Meeting.
The presentation will be led by CEO and Co-Founder Timothy Lu, MD, PhD, and President, Head of R&D and Chief Medical Officer Kanya Rajangam, MD, PhD. Participants can join via phone at (877) 524-8416 (domestic) or +1 (412) 902-1028 (international). The webcast will be available on the company's website and archived for 90 days.
Senti Biosciences (NASDAQ: SNTI) has released a Virtual Investor KOL Connect segment featuring a moderated discussion between two key experts in the field of leukemia research and treatment. The segment features Dr. Stephen Strickland, Director of Leukemia Research at Sarah Cannon Research Institute, and Dr. Kanya Rajangam, President, Head of R&D and Chief Medical Officer of Senti Bio.
The discussion focused on acute myeloid leukemia (AML), current treatment approaches, and unmet medical needs. The experts specifically highlighted Senti Bio's lead program, SENTI-202, and reviewed both clinical and preclinical data released by the company to date. The virtual segment is now available for viewing online.
Senti Biosciences (NASDAQ: SNTI), a clinical-stage biotechnology company specializing in Gene Circuit platform for cell and gene therapies, has announced its participation in the Virtual Investor Closing Bell Series. The event is scheduled for Wednesday, April 23, 2025, at 4:00 PM ET.
The company's leadership team, including Timothy Lu, MD, PhD (CEO and Co-Founder) and Kanya Rajangam, MD, PhD (President, Head of R&D and Chief Medical Officer), will deliver a corporate overview followed by a live Q&A session. The presentation will be accessible through a live video webcast on the Events page of Senti Bio's website (www.sentibio.com), with a replay available for 90 days following the event.
Senti Biosciences (SNTI) has appointed James B. Trager, Ph.D. to its Scientific Advisory Board. Dr. Trager brings over 25 years of expertise in cellular therapy development and has contributed to nearly 50 publications, abstracts, and patents.
As former Chief Scientific Officer of Nkarta Therapeutics, he led multiple discovery assets through IND and developed CAR NK product opportunities. At Dendreon Pharmaceuticals, he served as Vice President of Research and Product Development, supporting sipuleucel-T development. His experience includes senior roles at Geron , where he contributed to human telomerase cloning.
Dr. Trager will support Senti Bio's development of Logic Gating technology and the SENTI-202 program for AML treatment. Throughout his career, he has managed over 100 scientists, engineers, and technicians in cell therapy development.
Senti Biosciences (NASDAQ: SNTI), a clinical-stage biotechnology company developing next-generation cell and gene therapies, has announced its participation in the Webull Corporate Connect Service (CCS) platform. The company, which is advancing off-the-shelf CAR-NK cell therapy programs for oncology indications with its lead candidate SENTI-202 in clinical development for acute myeloid leukemia (AML), aims to enhance transparency and communication with shareholders through this new platform.
Through Webull CCS, Senti Bio will share corporate content including company news, earnings reports, product updates, and presentations. CEO Timothy Lu emphasized the company's commitment to maintaining effective communication with shareholders and building market awareness as they continue their clinical execution.
Senti Biosciences (NASDAQ: SNTI) announced three abstract presentations at the upcoming AACR Annual Meeting 2025 (April 25-30, Chicago), showcasing new data from their lead product SENTI-202, a CAR NK cell therapy for relapsed/refractory acute myeloid leukemia (r/r AML).
The presentations include an oral minisymposium on clinical data, and two poster sessions focusing on correlative data and preclinical characterization of their Logic Gate technology. The preclinical data demonstrates that EMCN inhibitory CAR (NOT gate) effectively protects healthy bone marrow cells from on-target off-tumor toxicity in vivo.
Dr. Kanya Rajangam, President, Head of R&D and Chief Medical Officer, emphasized the potential of SENTI-202 for treating r/r AML and highlighted the broader applications of Logic Gating technology in oncology for selective cancer targeting while preserving healthy cells.
Senti Biosciences (NASDAQ: SNTI) has reported its Q4 and full-year 2024 financial results, highlighting significant clinical progress and financial developments. The company's lead product SENTI-202 showed promising initial Phase 1 results, with 2 out of 3 relapsed/refractory AML patients achieving MRD negative complete remission at the lowest dose level, maintaining remission as of March 2025.
The company substantially strengthened its financial position through a $47.6 million PIPE financing led by Celadon Partners, with participation from notable investors. The net proceeds of $45.1 million are expected to extend the company's runway into 2026. Additionally, Senti Bio received $1.5 million from CIRM, bringing total grant funding to $6.4 million.
Financial results show cash and cash equivalents of $48.3 million as of December 31, 2024. Q4 R&D expenses decreased to $7.8 million from $9.1 million year-over-year, while G&A expenses reduced to $8.4 million from $9.3 million. The company reported a Q4 net loss of $0.6 million ($0.67 per share) and a full-year 2024 net loss of $52.8 million ($12.03 per share).
FAQ
What is the current stock price of Senti Bioscience (SNTI)?
What is the market cap of Senti Bioscience (SNTI)?
